SY
Synovics Pharmaceuticals, Inc.
SYVC · OTC
$0.00 +0.00% (+$0.00)
Piotroski F-Score Weak
3/9Valuation
-
N/A P/FCF N/A
P/S N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
-
N/A ROE N/A
ROA N/A
Asset turnover N/A
Debt
-
N/A Debt/Assets N/A
Int. coverage N/A
Net debt/EBITDA N/A
Stability
50 /100
Moderate Beta -0.29x
EPS volatility N/A
Profitable years N/A
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na SYVC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Christopher J. Flynn
Employees
155
Headquarters
Fort Lauderdale